Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia.
Post SM, Ma H, Malaney P, Zhang X, Aitken MJL, Mak PY, Ruvolo VR, Yasuhiro T, Kozaki R, Chan LE, Ostermann LB, Konopleva M, Carter BZ, DiNardo C, Andreeff MD, Khoury JD, Ruvolo PP. Post SM, et al. Among authors: ostermann lb. Haematologica. 2022 Jun 1;107(6):1311-1322. doi: 10.3324/haematol.2021.278369. Haematologica. 2022. PMID: 34732043 Free PMC article.
Mdm2/p53 levels in bone marrow mesenchymal stromal cells is essential for maintaining the hematopoietic niche in response to DNA damage.
Pourebrahim R, Montoya RH, Alaniz Z, Ostermann L, Lin PP, Liu B, Ayoub E, Burks JK, Andreeff M. Pourebrahim R, et al. Among authors: ostermann l. Res Sq [Preprint]. 2023 Mar 2:rs.3.rs-2544760. doi: 10.21203/rs.3.rs-2544760/v1. Res Sq. 2023. Update in: Cell Death Dis. 2023 Jun 23;14(6):371. doi: 10.1038/s41419-023-05844-7 PMID: 36909480 Free PMC article. Updated. Preprint.
FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML.
Jia Y, Zhang W, Basyal M, Chang KH, Ostermann L, Burks JK, Ly C, Mu-Mosley H, Zhang Q, Han X, Fogler WE, Magnani JL, Lesegretain A, Zal AA, Zal T, Andreeff M. Jia Y, et al. Among authors: ostermann l. Leukemia. 2023 Jun;37(6):1379-1383. doi: 10.1038/s41375-023-01897-x. Epub 2023 Apr 21. Leukemia. 2023. PMID: 37085610 Free PMC article. No abstract available.
Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics.
Carter BZ, Mak PY, Tao W, Ayoub E, Ostermann LB, Huang X, Loghavi S, Boettcher S, Nishida Y, Ruvolo V, Hughes PE, Morrow PK, Haferlach T, Kornblau S, Muftuoglu M, Andreeff M. Carter BZ, et al. Blood Cancer J. 2023 Apr 24;13(1):57. doi: 10.1038/s41408-023-00830-w. Blood Cancer J. 2023. PMID: 37088806 Free PMC article.
Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics.
Carter BZ, Mak PY, Tao W, Ayoub E, Ostermann LB, Huang X, Loghavi S, Boettcher S, Nishida Y, Ruvolo V, Hughes PE, Morrow PK, Haferlach T, Kornblau S, Muftuoglu M, Andreeff M. Carter BZ, et al. Among authors: ostermann lb. Blood Cancer J. 2023 May 17;13(1):80. doi: 10.1038/s41408-023-00857-z. Blood Cancer J. 2023. PMID: 37193700 Free PMC article. No abstract available.
Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells.
Carter BZ, Mak PY, Muftuoglu M, Tao W, Ke B, Pei J, Bedoy AD, Ostermann LB, Nishida Y, Isgandarova S, Sobieski M, Nguyen N, Powell RT, Martinez-Moczygemba M, Stephan C, Basyal M, Pemmaraju N, Boettcher S, Ebert BL, Shpall EJ, Wallner B, Morgan RA, Karras GI, Moll UM, Andreeff M. Carter BZ, et al. Among authors: ostermann lb. Blood. 2023 Sep 21;142(12):1056-1070. doi: 10.1182/blood.2022019047. Blood. 2023. PMID: 37339579 Free PMC article.
43 results